Healthcare Wire Texas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.

Press releases published on September 9, 2026

Sep. 9, 2026

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

Indeterminate GlobeNewswire

Sep. 9, 2026

electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

Indeterminate GlobeNewswire

Sep. 9, 2026

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Indeterminate GlobeNewswire

Sep. 9, 2026

Persephone Biosciences Celebrates First Birthday of Bloom and Thrive Synbiotics, with More Than 1.5 Million Doses Manufactured

Indeterminate GlobeNewswire

Sep. 9, 2026

Weight Watchers Appoints Stephen Bye as Chief Executive Officer

Indeterminate GlobeNewswire

Sep. 9, 2026

Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer

Indeterminate GlobeNewswire

Sep. 9, 2026

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

Indeterminate GlobeNewswire

Sep. 9, 2026

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Indeterminate GlobeNewswire

Sep. 9, 2026

Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities

Indeterminate GlobeNewswire

Sep. 9, 2026

Aktis Oncology to Present at Upcoming September Investor Conferences

Indeterminate GlobeNewswire

Sep. 9, 2026

MBX Biosciences to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 9, 2026

UF Health Collaborates with R1 on AI-Powered Revenue Cycle Transformation with Phare OS

Indeterminate GlobeNewswire

Sep. 9, 2026

SOTIO Doses First Patient in Phase 1/2 CADENCIA-01 Clinical Trial of SOT109, a CDH17-Targeting ADC for Colorectal Cancer

Indeterminate GlobeNewswire

Sep. 9, 2026

Sinaptica Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Indeterminate GlobeNewswire

Sep. 9, 2026

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

Indeterminate GlobeNewswire

Sep. 9, 2026

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

Indeterminate GlobeNewswire

Sep. 9, 2026

Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada

Indeterminate GlobeNewswire

Sep. 9, 2026

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer

Indeterminate GlobeNewswire

Sep. 9, 2026

NervGen to Host Inaugural R&D Day on September 30, 2026

Indeterminate GlobeNewswire

Sep. 9, 2026

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

Indeterminate GlobeNewswire